Cargando…

Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press LLC 2021
Materias:	Meeting Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871664/ https://www.ncbi.nlm.nih.gov/pubmed/33614183 http://dx.doi.org/10.6004/jadpro.2021.12.1.13

Ejemplares similares

New CAR Designs: Highlights From SOHO 2020
Publicado: (2021)

Emerging Therapies in Myelofibrosis: Highlights From SOHO 2020
Publicado: (2021)

Integrating Novel Agents in Relapsed or Refractory Hodgkin Lymphoma: Highlights From SOHO 2020
Publicado: (2021)

Immunotherapy for T-Cell ALL and T-NHL: Highlights From SOHO 2020
Publicado: (2021)

Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020
Publicado: (2021)

Managing Relapsed Disease in Peripheral T-Cell Lymphoma: Highlights From SOHO 2020
Publicado: (2021)

Predicting Drug Response in Acute Lymphoblastic Leukemia: Highlights From SOHO 2020
Publicado: (2021)

Therapeutic Updates for Richter Syndrome: Highlights From SOHO 2021
Publicado: (2022)

Updates on Therapeutic Advancements in Relapsed or Refractory Multiple Myeloma: Highlights From SOHO 2020
Publicado: (2021)

The Next Wave of Novel Agents in Aggressive B-Cell Lymphoma: Highlights From SOHO 2021
Publicado: (2022)

Updates on Clinical Trials for Myelofibrosis: Highlights From SOHO 2021
Publicado: (2022)

Beyond Hyper-CVAD in ALL: Highlights From SOHO 2021
Publicado: (2022)

Immunotherapy Approaches in T-Cell Lymphoma: Highlights From SOHO 2021
Publicado: (2022)

Targeting p53 in MDS: Highlights From SOHO 2021
Publicado: (2022)

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Publicado: (2022)

BCMA-Directed CAR T Cells in Relapsed Refractory Multiple Myeloma: Highlights From SOHO 2021
Publicado: (2022)

Novel Treatment Approaches in Relapsed/Refractory Mantle Cell Lymphoma: Highlights From SOHO 2021
Publicado: (2022)

The Advanced Practitioner’s Role in Treating Patients With Hematologic Malignancies: Highlights From SOHO 2020
por: Price, Allyson
Publicado: (2021)

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
por: Lee, Sangmin, et al.
Publicado: (2022)

Management of myelodysplastic syndromes after failure of response to hypomethylating agents
por: Gil-Perez, Angela, et al.
Publicado: (2019)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence
por: Nazha, Aziz, et al.
Publicado: (2019)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes
por: Abbas, Hussein A., et al.
Publicado: (2021)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
por: Sohn, Sang Kyun, et al.
Publicado: (2018)

Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome
por: Grimm, Juliane, et al.
Publicado: (2022)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

From cell surface to nucleus: CCRL2 regulates response to hypomethylating agents in myelodysplastic syndromes
por: Saygin, Caner
Publicado: (2023)

Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells
por: Hu, Xiaoyan, et al.
Publicado: (2023)

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
por: Zhao, Guangjie, et al.
Publicado: (2021)

The Soho mission
por: Fleck, B, et al.
Publicado: (1996)

Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes
por: Kim, Yundeok, et al.
Publicado: (2014)

Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents
por: Kang, Ka-Won, et al.
Publicado: (2020)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

The Advanced Practitioner's Role in Treating Patients With Hematologic Malignancies: Highlights From SOHO 2021
por: Geppner, Alexis C.
Publicado: (2022)

The first results from Soho
por: Fleck, B, et al.
Publicado: (1997)

Highlights from Science Policy Interface sessions at the One Health Congress 2020
por: Vanlangendonck, Chris, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oilaepf4g1dt0u6b1gmhhdkbj6